Enimmune Corporation Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2014)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2014
NCT02777411
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Enimmune Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

ev71 vaccine (3 trials)

Drugs in Phase 2 Trials (1)

aluminum hydroxide (Gaviscon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Enterovirus Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2